<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232258</url>
  </required_header>
  <id_info>
    <org_study_id>DRI4553</org_study_id>
    <nct_id>NCT00232258</nct_id>
  </id_info>
  <brief_title>Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study</brief_title>
  <acronym>NICE</acronym>
  <official_title>Nolpitantium Besylate in Patients With Mild to Moderate Ulcerative Colitis, a Double-Blind, Placebo Controlled Efficacy and Safety, 8 Week Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy on clinical symptoms, mucosal histology and endoscopic
      mucosal appearance of two doses of SR140333B against placebo in patients with mild to
      moderate ulcerative colitis resistant to treatment with 5-ASA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with active mild to moderate ulcerative colitis that has not responded to a minimum
      of 4 weeks of 5-ASA will be randomized to receive single daily doses of either placebo, 600
      mg SR140333B or 1800 mg of SR140333B for eight weeks. Patients will undergo baseline and end
      of study sigmoidoscopic assessments and complete daily symptom diaries during the study.
      Ulcerative colitis disease activity will be measured by both the overall and component
      subscores of the Mayo Disease Activity Index.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical remission at 8 weeks defined as a clinical Mayo subscore &lt;/= 1</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response defined as at least 3 point reduction from baseline on Clinical Mayo Sub-score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global change in overall Disease Activity Index</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal pain score at 8 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
  </secondary_outcome>
  <enrollment type="Actual">307</enrollment>
  <condition>Ulcerative Colitis</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nolpitantium besylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at least 18 years

          -  Ulcerative colitis of at least 6 months duration

          -  Patient's ulcerative colitis should remain active while taking 5-ASA or sulfasalazine
             for at least 4 week

          -  If taking corticosteroids, dose must be stable for at least 2 weeks prior to
             enrollment and not exceed 20 mg per day (prednisolone equivalent)

        Exclusion Criteria:

          -  Crohn's disease

          -  Colonic dysplasia

          -  Stool culture positive for enteric pathogens

          -  Concurrent cancer or unstable medical condition

          -  Recent treatment with monoclonal antibody

          -  Recent introduction of thiazolidinedione

          -  Recent treatment with methotrexate or cyclosporine

          -  Recent treatment with an antibiotic prescribed for ulcerative colitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gert Van Assche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhizen Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Diegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.sanofi-aventis.com</url>
  </link>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2005</study_first_submitted>
  <study_first_submitted_qc>October 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2005</study_first_posted>
  <last_update_submitted>December 9, 2008</last_update_submitted>
  <last_update_submitted_qc>December 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>NK1 Antagonist</keyword>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>Mesalamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

